Inhibitor of ppGalNAc-T3-mediated O-glycosylation blocks cancer cell invasiveness and lowers FGF23 levels

eLife

Volumn 6, Issue , 2017, Pages

  Song, Lina ^a   Linstedt, Adam D ^a  

^a CARNEGIE MELLON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR 23; N ACETYLGALACTOSAMINYLTRANSFERASE; ANTINEOPLASTIC AGENT; ENZYME INHIBITOR; FIBROBLAST GROWTH FACTOR; POLYPEPTIDE N-ACETYLGALACTOSAMINYLTRANSFERASE;

ANIMAL EXPERIMENT; ARTICLE; BREAST CANCER; CANCER SCREENING; CELL INVASION; CELL PROLIFERATION; CHRONIC KIDNEY FAILURE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; FLUORESCENCE; GENE EXPRESSION; GENETIC TRANSFECTION; GLYCOSYLATION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; MOUSE; NEOPLASM; NONHUMAN; PROTEIN EXPRESSION; TUMOR INVASION; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; CELL MOTION; DRUG EFFECTS; ISOLATION AND PURIFICATION; METABOLISM; PRECLINICAL STUDY; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL MOVEMENT; DRUG EVALUATION, PRECLINICAL; ENZYME INHIBITORS; FIBROBLAST GROWTH FACTORS; GLYCOSYLATION; MICE; N-ACETYLGALACTOSAMINYLTRANSFERASES;

EID: 85018895489     PISSN: None     EISSN: 2050084X     Source Type: Journal    
DOI: 10.7554/eLife.24051     Document Type: Article

References (40)

1. Bai X, Miao D, Xiao S, Qiu D, St-Arnaud R, Petkovich M, Gupta A, Goltzman D, Karaplis AC. 2016. CYP24 inhibition as a therapeutic target in FGF23-mediated renal phosphate wasting disorders. Journal of Clinical Investigation 126:667–680. doi: 10.1172/JCI81928, PMID: 26784541
2. Bennett EP, Mandel U, Clausen H, Gerken TA, Fritz TA, Tabak LA. 2012. Control of mucin-type O-glycosylation: a classification of the polypeptide GalNAc-transferase gene family. Glycobiology 22:736–756. doi: 10.1093/glycob/cwr182, PMID: 22183981
3. Brockhausen I. 2006. Mucin-type O-glycans in human Colon and breast Cancer: glycodynamics and functions. EMBO Reports 7:599–604. doi: 10.1038/sj.embor.7400705, PMID: 16741504
4. Brooks SA, Carter TM, Bennett EP, Clausen H, Mandel U. 2007. Immunolocalisation of members of the polypeptide N-acetylgalactosaminyl transferase (ppGalNAc-T) family is consistent with biologically relevant altered cell surface glycosylation in breast Cancer. Acta Histochemica 109:273–284. doi: 10.1016/j.acthis.2007.02.009, PMID: 17448526
5. Chefetz I, Sprecher E. 2009. Familial tumoral calcinosis and the role of O-glycosylation in the maintenance of phosphate homeostasis. Biochimica Et Biophysica Acta (BBA)-Molecular Basis of Disease 1792:847–852. doi: 10.1016/j.bbadis.2008.10.008, PMID: 19013236
6. Degirolamo C, Sabbà C, Moschetta A. 2016. Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23. Nature Reviews Drug Discovery 15:51–69. doi: 10.1038/nrd.2015.9, PMID: 26567701
7. Eckardt KU, Kasiske BL. 2009. Kidney disease: improving global outcomes. Nature Reviews Nephrology 5:650–657. doi: 10.1038/nrneph.2009.153, PMID: 19786993
8. Evan GI, Lewis GK, Ramsay G, Bishop JM. 1985. Isolation of monoclonal antibodies specific for human c-myc proto-oncogene product. Molecular and Cellular Biology 5:3610–3616. doi: 10.1128/MCB.5.12.3610, PMID: 3 915782
9. Fukumoto S. 2016. FGF23-FGF receptor/Klotho pathway as a New Drug target for disorders of bone and Mineral metabolism. Calcified Tissue International 98:334–340. doi: 10.1007/s00223-015-0029-y, PMID: 26126 937
10. Gao Y, Liu Z, Feng J, Sun Q, Zhang B, Zheng W, Ma W. 2013. Expression pattern of polypeptide N-acetylgalactosaminyltransferase-10 in gastric carcinoma. Oncology Letters 5:113–116. doi: 10.3892/ol.2012.980, PMID: 23255904
11. Goetz R, Nakada Y, Hu MC, Kurosu H, Wang L, Nakatani T, Shi M, Eliseenkova AV, Razzaque MS, Moe OW, Kuro-o M, Mohammadi M. 2010. Isolated C-terminal tail of FGF23 alleviates hypophosphatemia by inhibiting FGF23-FGFR-Klotho complex formation. PNAS 107:407–412. doi: 10.1073/pnas.0902006107, PMID: 19966287
12. Harada Y, Izumi H, Noguchi H, Kuma A, Kawatsu Y, Kimura T, Kitada S, Uramoto H, Wang KY, Sasaguri Y, Hijioka H, Miyawaki A, Oya R, Nakayama T, Kohno K, Yamada S. 2016. Strong expression of polypeptide N-acetylgalactosaminyltransferase 3 independently predicts shortened disease-free survival in patients with early stage oral squamous cell carcinoma. Tumor Biology 37:1357–1368. doi: 10.1007/s13277-015-3928-7, PMID: 26296622
13. Ichikawa S, Gray AK, Padgett LR, Allen MR, Clinkenbeard EL, Sarpa NM, White KE, Econs MJ. 2014. Genetic rescue of glycosylation-deficient Fgf23 in the Galnt3 knockout mouse. Endocrinology 155:3891–3898. doi: 10.1210/en.2014-1199, PMID: 25051439
14. Isakova T, Ix JH, Sprague SM, Raphael KL, Fried L, Gassman JJ, Raj D, Cheung AK, Kusek JW, Flessner MF, Wolf M, Block GA. 2015. Rationale and approaches to phosphate and fibroblast growth factor 23 reduction in CKD. Journal of the American Society of Nephrology 26:2328–2339. doi: 10.1681/ASN.2015020117, PMID: 25 967123
15. Jesch SA, Lewis TS, Ahn NG, Linstedt AD. 2001. Mitotic phosphorylation of golgi reassembly stacking protein 55 by mitogen-activated protein kinase ERK2. Molecular Biology of the Cell 12:1811–1817. doi: 10.1091/mbc.12.6.1811, PMID: 11408587
16. Kato K, Jeanneau C, Tarp MA, Benet-Pagès A, Lorenz-Depiereux B, Bennett EP, Mandel U, Strom TM, Clausen H. 2006. Polypeptide GalNAc-transferase T3 and familial tumoral calcinosis. secretion of fibroblast growth factor 23 requires O-glycosylation. Journal of Biological Chemistry 281:18370–18377. doi: 10.1074/jbc.M602469200, PMID: 16638743
17. Kitada S, Yamada S, Kuma A, Ouchi S, Tasaki T, Nabeshima A, Noguchi H, Wang KY, Shimajiri S, Nakano R, Izumi H, Kohno K, Matsumoto T, Sasaguri Y. 2013. Polypeptide N-acetylgalactosaminyl transferase 3 independently predicts high-grade tumours and poor prognosis in patients with renal cell carcinomas. British Journal of Cancer 109:472–481. doi: 10.1038/bjc.2013.331, PMID: 23799843
18. Kohsaki T, Nishimori I, Nakayama H, Miyazaki E, Enzan H, Nomoto M, Hollingsworth MA, Onishi S. 2000. Expression of UDP-GalNAc: polypeptide N-acetylgalactosaminyltransferase isozymes T1 and T2 in human colorectal Cancer. Journal of Gastroenterology 35:840–848. doi: 10.1007/s005350070021, PMID: 11085493
19. Kuan SF, Byrd JC, Basbaum C, Kim YS. 1989. Inhibition of mucin glycosylation by aryl-N-acetyl-alpha-galactosaminides in human Colon cancer cells. The Journal of Biological Chemistry 264:19271–19277. PMID: 2509474
20. Mochizuki Y, Ito K, Izumi H, Kohno K, Amano J. 2013. Expression of polypeptide N-acetylgalactosaminyl transferase-3 and its association with clinicopathological factors in thyroid carcinomas. Thyroid 23:1553–1560. doi: 10.1089/thy.2012.0613, PMID: 23659732
21. Moremen KW, Tiemeyer M, Nairn AV. 2012. Vertebrate protein glycosylation: diversity, synthesis and function. Nature Reviews Molecular Cell Biology 13:448–462. doi: 10.1038/nrm3383, PMID: 22722607
22. Mukhopadhyay S, Bachert C, Smith DR, Linstedt AD. 2010. Manganese-induced trafficking and turnover of the cis-Golgi glycoprotein GPP130. Molecular Biology of the Cell 21:1282–1292. doi: 10.1091/mbc.E09-11-0985, PMID: 20130081
23. Patsos G, Hebbe-Viton V, Robbe-Masselot C, Masselot D, San Martin R, Greenwood R, Paraskeva C, Klein A, Graessmann M, Michalski JC, Gallagher T, Corfield A. 2009. O-glycan inhibitors generate aryl-glycans, induce apoptosis and lead to growth inhibition in colorectal Cancer cell lines. Glycobiology 19:382–398. doi: 10.1093/glycob/cwn149, PMID: 19122213
24. Peng RQ, Wan HY, Li HF, Liu M, Li X, Tang H. 2012. MicroRNA-214 suppresses growth and invasiveness of cervical Cancer cells by targeting UDP-N-acetyl-a-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 7. Journal of Biological Chemistry 287:14301–14309. doi: 10.1074/jbc.M111.337642, PMID: 22399294
25. Puri S, Bachert C, Fimmel CJ, Linstedt AD. 2002. Cycling of early golgi proteins via the cell surface and endosomes upon lumenal pH disruption. Traffic 3:641–653. doi: 10.1034/j.1600-0854.2002.30906.x, PMID: 121 91016
26. Revoredo L, Wang S, Bennett EP, Clausen H, Moremen KW, Jarvis DL, Ten Hagen KG, Tabak LA, Gerken TA. 2016. Mucin-type O-glycosylation is controlled by short-and long-range glycopeptide substrate recognition that varies among members of the polypeptide GalNAc transferase family. Glycobiology 26:360–376. doi: 10.1093/glycob/cwv108, PMID: 26610890
27. Rowe PS. 2015. A unified model for bone-renal mineral and energy metabolism. Current Opinion in Pharmacology 22:64–71. doi: 10.1016/j.coph.2015.03.006, PMID: 25880364
28. Röttger S, White J, Wandall HH, Olivo JC, Stark A, Bennett EP, Whitehouse C, Berger EG, Clausen H, Nilsson T. 1998. Localization of three human polypeptide GalNAc-transferases in HeLa cells suggests initiation of O-linked glycosylation throughout the golgi apparatus. Journal of Cell Science 111:45–60. PMID: 9394011
29. Schjoldager KT, Clausen H. 2012. Site-specific protein O-glycosylation modulates proprotein processing-deciphering specific functions of the large polypeptide GalNAc-transferase gene family. Biochimica Et Biophysica Acta (BBA)-General Subjects 1820:2079–2094. doi: 10.1016/j.bbagen.2012.09.014, PMID: 2302250 8
30. Schjoldager KT, Joshi HJ, Kong Y, Goth CK, King SL, Wandall HH, Bennett EP, Vakhrushev SY, Clausen H. 2015. Deconstruction of O-glycosylation–GalNAc-T isoforms direct distinct subsets of the O-glycoproteome. EMBO Reports 16:1713–1722. doi: 10.15252/embr.201540796, PMID: 26566661
31. Schjoldager KT, Vakhrushev SY, Kong Y, Steentoft C, Nudelman AS, Pedersen NB, Wandall HH, Mandel U, Bennett EP, Levery SB, Clausen H. 2012. Probing isoform-specific functions of polypeptide GalNAc-transferases using zinc finger nuclease glycoengineered SimpleCells. PNAS 109:9893–9898. doi: 10.1073/pnas.1203563109, PMID: 22566642
32. Schjoldager KT, Vester-Christensen MB, Bennett EP, Levery SB, Schwientek T, Yin W, Blixt O, Clausen H. 2010. O-glycosylation modulates proprotein convertase activation of angiopoietin-like protein 3: possible role of polypeptide GalNAc-transferase-2 in regulation of concentrations of plasma lipids. Journal of Biological Chemistry 285:36293–36303. doi: 10.1074/jbc.M110.156950, PMID: 20837471
33. Schjoldager KT, Vester-Christensen MB, Goth CK, Petersen TN, Brunak S, Bennett EP, Levery SB, Clausen H. 2011. A systematic study of site-specific GalNAc-type O-glycosylation modulating proprotein convertase processing. Journal of Biological Chemistry 286:40122–40132. doi: 10.1074/jbc.M111.287912, PMID: 21937429
34. Smith ER. 2014. The use of fibroblast growth factor 23 testing in patients with kidney disease. Clinical Journal of the American Society of Nephrology 9:1283–1303. doi: 10.2215/CJN.10941013, PMID: 24578336
35. Song L, Bachert C, Schjoldager KT, Clausen H, Linstedt AD. 2014. Development of isoform-specific sensors of polypeptide GalNAc-transferase activity. Journal of Biological Chemistry 289:30556–30566. doi: 10.1074/jbc.M114.599563, PMID: 25225288
36. Sun N, Guo Y, Liu W, Densmore M, Shalhoub V, Erben RG, Ye L, Lanske B, Yuan Q. 2015. FGF23 neutralization improves bone quality and osseointegration of titanium implants in chronic kidney disease mice. Scientific Reports 5:8304. doi: 10.1038/srep08304, PMID: 25665715
37. Szász AM, Lánczky A, Nagy Á, Förster S, Hark K, Green JE, Boussioutas A, Busuttil R, Szabó A, Győrffy B. 2016. Cross-validation of survival associated biomarkers in gastric Cancer using transcriptomic data of 1,065 patients. Oncotarget 7:49322–49333. doi: 10.18632/oncotarget.10337, PMID: 27384994
38. Tagliabracci VS, Engel JL, Wiley SE, Xiao J, Gonzalez DJ, Nidumanda Appaiah H, Koller A, Nizet V, White KE, Dixon JE. 2014. Dynamic regulation of FGF23 by Fam20C phosphorylation, GalNAc-T3 glycosylation, and furin proteolysis. PNAS 111:5520–5525. doi: 10.1073/pnas.1402218111, PMID: 24706917
39. van der Post S, Subramani DB, Bäckström M, Johansson ME, Vester-Christensen MB, Mandel U, Bennett EP, Clausen H, Dahlén G, Sroka A, Potempa J, Hansson GC. 2013. Site-specific O-glycosylation on the MUC2 mucin protein inhibits cleavage by the Porphyromonas gingivalis secreted cysteine protease (RgpB). Journal of Biological Chemistry 288:14636–14646. doi: 10.1074/jbc.M113.459479, PMID: 23546879
40. Wang ZQ, Bachvarova M, Morin C, Plante M, Gregoire J, Renaud MC, Sebastianelli A, Bachvarov D. 2014. Role of the polypeptide N-acetylgalactosaminyltransferase 3 in ovarian Cancer progression: possible implications in abnormal mucin O-glycosylation. Oncotarget 5:544–560. doi: 10.18632/oncotarget.1652, PMID: 24504219